These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 36592323)

  • 1. Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities.
    Jiang Y; Chen Y; Yu Q; Shi Y
    BioDrugs; 2023 Jan; 37(1):35-55. PubMed ID: 36592323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?
    Amin M; No DJ; Egeberg A; Wu JJ
    Am J Clin Dermatol; 2018 Feb; 19(1):1-13. PubMed ID: 29080066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry.
    Strober B; Karki C; Mason M; Guo N; Holmgren SH; Greenberg JD; Lebwohl M
    J Am Acad Dermatol; 2018 Feb; 78(2):323-332. PubMed ID: 29051036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review.
    Kamata M; Tada Y
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32121574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-immune functions of inflammatory cytokines targeted by anti-psoriatic biologics: a review.
    Lee TL; Tsai TF
    Inflamm Res; 2022 Feb; 71(2):157-168. PubMed ID: 34981130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Moderate-to-Severe Psoriasis.
    Greenzaid J; Feldman S
    Clin Pharmacokinet; 2024 Feb; 63(2):137-153. PubMed ID: 38280146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities.
    Mateu-Arrom L; Puig L
    Expert Rev Clin Pharmacol; 2024 Apr; 17(4):363-379. PubMed ID: 38603464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Insight on the Possible Association between Inflammatory Bowel Disease and Biologic Therapy with IL-17 Inhibitors in Psoriasis Patients.
    Orzan OA; Țieranu CG; Olteanu AO; Dorobanțu AM; Cojocaru A; Mihai MM; Popa LG; Gheorghiu AM; Giurcăneanu C; Ion A
    Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologics and Psoriasis: The Beat Goes On.
    Kim HJ; Lebwohl MG
    Dermatol Clin; 2019 Jan; 37(1):29-36. PubMed ID: 30466686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment.
    Ten Bergen LL; Petrovic A; Krogh Aarebrot A; Appel S
    Scand J Immunol; 2020 Oct; 92(4):e12946. PubMed ID: 32697374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review.
    Thatiparthi A; Martin A; Liu J; Egeberg A; Wu JJ
    Am J Clin Dermatol; 2021 Jul; 22(4):425-442. PubMed ID: 33861409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evidence-based review of the mechanism of action, efficacy, and safety of biologic therapies in the treatment of psoriasis and psoriatic arthritis.
    Brezinski EA; Armstrong AW
    Curr Med Chem; 2015; 22(16):1930-42. PubMed ID: 25921645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.
    Borren NZ; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1736-1743.e4. PubMed ID: 30616024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies.
    Elyoussfi S; Thomas BJ; Ciurtin C
    Rheumatol Int; 2016 May; 36(5):603-12. PubMed ID: 26892034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe and acute complications of biologics in psoriasis.
    Oussedik E; Patel NU; Cash DR; Gupta AS; Feldman SR
    G Ital Dermatol Venereol; 2017 Dec; 152(6):586-596. PubMed ID: 28895664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.
    Yang K; Oak ASW; Elewski BE
    Am J Clin Dermatol; 2021 Mar; 22(2):173-192. PubMed ID: 33301128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.
    Armstrong AW; Read C
    JAMA; 2020 May; 323(19):1945-1960. PubMed ID: 32427307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis.
    Ovejero-Benito MC; Muñoz-Aceituno E; Reolid A; Saiz-Rodríguez M; Abad-Santos F; Daudén E
    Am J Clin Dermatol; 2018 Apr; 19(2):209-222. PubMed ID: 28921458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
    Menter A; Gottlieb A; Feldman SR; Van Voorhees AS; Leonardi CL; Gordon KB; Lebwohl M; Koo JY; Elmets CA; Korman NJ; Beutner KR; Bhushan R
    J Am Acad Dermatol; 2008 May; 58(5):826-50. PubMed ID: 18423260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In the Real World: Infections Associated with Biologic and Small Molecule Therapies in Psoriatic Arthritis and Psoriasis.
    Siegel SAR; Winthrop KL
    Curr Rheumatol Rep; 2019 Jun; 21(7):36. PubMed ID: 31172303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.